NEW YORK – Roche announced on Thursday that it will offer Ibex Medical Analytics' artificial intelligence-based digital pathology tools on its Navify Digital Pathology software platform.
The Navify platform allows pathologists to access third-party AI technology, as well as Roche's AI-based image analysis tools.
Ibex's Galen solutions for breast and prostate cancer diagnosis help support case prioritization, determine the cancer grading and subtype, and identify non-cancerous features, the company said in a statement. The algorithms are for research use only in the US and CE-marked for in vitro diagnostic use in Europe.
Both Roche's Navify platform and Ibex's algorithms run on the Amazon Web Services cloud infrastructure.
"Our collaboration with Roche is driving new AI-powered workflows that help pathologists and laboratories realize the full potential of going digital," Ibex CEO and Cofounder Joseph Mossel said in a statement. "The next phase in the evolution of digital pathology is open platforms that enable technology providers to join forces and offer integrated software solutions that improve lab efficiency, biopsy review, and ultimately the quality of patient care."
In 2021, Ibex and Roche entered an agreement to jointly develop an embedded image analysis workflow for pathologists.